Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
16
2
2020
medline:
19
8
2020
entrez:
16
2
2020
Statut:
ppublish
Résumé
The legalisation of cannabis in a growing number of jurisdictions has led to increasing interest in its potential therapeutic effects in a range of disorders, including cutaneous conditions. Cannabinoids have been used as natural medicines for centuries; however, their biological activity in the skin is a new area of study. Recent data suggest that cannabinoids are involved in neuro-immuno-endocrine modulation of skin functioning, yet their effect on the features of dermatologic conditions is unclear. This article sought to review the mechanisms by which cannabinoids regulate skin functioning through the lens of relevance to treatment of dermatologic diseases looking at the effects of cannabinoids on a range of cellular activities and dermatologic conditions both in vitro and in vivo. We identified studies demonstrating an inhibitory effect of cannabinoids on skin inflammation, proliferation, fibrosis, pain, and itch-biological mechanisms involved in the pathogenesis of many dermatologic conditions. Cannabinoids have the potential to expand the therapeutic repertoire of a wide spectrum of skin disorders. Given their widespread unregulated use by the general public, basic and clinical studies are required to elucidate the effectiveness and long-term effects of topical and systemic cannabinoids in cutaneous disorders.
Identifiants
pubmed: 32060787
doi: 10.1007/s40261-020-00894-7
pii: 10.1007/s40261-020-00894-7
doi:
Substances chimiques
Cannabinoids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-304Références
Hughes CE. The trajectories of cannabis and tobacco policies in the United States, Uruguay, Canada and Portugal: is more cross-substance learning possible outside the United States? Addiction. 2018;113(4):603–5.
pubmed: 28836314
doi: 10.1111/add.13954
Biro T, et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009;30(8):411–20.
pubmed: 19608284
pmcid: 2757311
doi: 10.1016/j.tips.2009.05.004
Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Exp Dermatol. 2009;18(8):669–79.
pubmed: 19664006
doi: 10.1111/j.1600-0625.2009.00923.x
Toth KF, et al. cannabinoid signaling in the skin: therapeutic potential of the “C(ut)annabinoid” system. Molecules. 2019;24(5):1223–91.
doi: 10.3390/molecules24050918
Solymosi K, Kofalvi A. Cannabis: a Treasure Trove or Pandora’s Box? Mini Rev Med Chem. 2017;17(13):1223–91.
pubmed: 27719666
Maccarrone M, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277–96.
pubmed: 25796370
pmcid: 4420685
doi: 10.1016/j.tips.2015.02.008
Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623–39.
pubmed: 30116049
doi: 10.1038/nrd.2018.115
Garcia-Gonzalez E, Galeazzi M, Selvi E. Can cannabinoids modulate fibrotic progression in systemic sclerosis? Isr Med Assoc J. 2016;18(3–4):156–8.
pubmed: 27228633
Karsak M, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007;316(5830):1494–7.
pubmed: 17556587
doi: 10.1126/science.1142265
Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.
pubmed: 19631507
doi: 10.1016/j.jclinepi.2009.06.006
Beiteke U, et al. Pain and pain management in dermatology. J Dtsch Dermatol Ges. 2015;13(10):967–87.
pubmed: 26408457
Soneji ND, et al. Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators. Life Sci. 2010;87(5–6):162–8.
pubmed: 20598325
doi: 10.1016/j.lfs.2010.06.003
Ellington HC, et al. The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology. 2002;42(7):966–75.
pubmed: 12069907
doi: 10.1016/S0028-3908(02)00040-0
Maida V, Corban J. Topical medical cannabis: a new treatment for wound pain-three cases of pyoderma gangrenosum. J Pain Symptom Manag. 2017;54(5):732–6.
doi: 10.1016/j.jpainsymman.2017.06.005
Malek N, et al. The importance of TRPV1-sensitisation factors for the development of neuropathic pain. Mol Cell Neurosci. 2015;65:1–10.
pubmed: 25662734
doi: 10.1016/j.mcn.2015.02.001
Oshita K, et al. CB(1) cannabinoid receptor stimulation modulates transient receptor potential vanilloid receptor 1 activities in calcium influx and substance P Release in cultured rat dorsal root ganglion cells. J Pharmacol Sci. 2005;97(3):377–85.
pubmed: 15750287
doi: 10.1254/jphs.FP0040872
Potenzieri C, et al. Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J Neurophysiol. 2008;100(5):2794–806.
pubmed: 18784270
pmcid: 2585399
doi: 10.1152/jn.90809.2008
Toth CC, et al. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain. 2010;6:16.
pubmed: 20236533
pmcid: 2845559
doi: 10.1186/1744-8069-6-16
Costa B, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007;556(1–3):75–83.
pubmed: 17157290
doi: 10.1016/j.ejphar.2006.11.006
Costa B, et al. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol. 2004;143(2):247–50.
pubmed: 15313881
doi: 10.1038/sj.bjp.0705920
Nurmikko TJ, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1–3):210–20.
pubmed: 17997224
doi: 10.1016/j.pain.2007.08.028
Chelliah MP, et al. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol. 2018;35(4):e224–7.
pubmed: 29786144
doi: 10.1111/pde.13545
Garibyan L, Rheingold CG, Lerner EA. Understanding the pathophysiology of itch. Dermatol Ther. 2013;26(2):84–91.
pubmed: 23551365
doi: 10.1111/dth.12025
Greaves MW. Pathogenesis and treatment of pruritus. Curr Allergy Asthma Rep. 2010;10(4):236–42.
pubmed: 20428977
doi: 10.1007/s11882-010-0117-z
Schlosburg JE, et al. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther. 2009;329(1):314–23.
pubmed: 19168707
pmcid: 2670585
doi: 10.1124/jpet.108.150136
Darmani NA, Pandya DK. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm (Vienna). 2000;107(8–9):931–45.
doi: 10.1007/s007020070043
Schlosburg JE, et al. CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. Psychopharmacology. 2011;216(3):323–31.
pubmed: 21340468
pmcid: 3606913
doi: 10.1007/s00213-011-2224-5
Gaffal E, et al. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy. 2013;68(8):994–1000.
pubmed: 23889474
doi: 10.1111/all.12183
Singh D, et al. Dangerous plants in dermatology: legal and controlled. Clin Dermatol. 2018;36(3):399–419.
pubmed: 29908582
doi: 10.1016/j.clindermatol.2018.03.013
Petrosino S, et al. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy. 2010;65(6):698–711.
pubmed: 19909294
doi: 10.1111/j.1398-9995.2009.02254.x
Dvorak M, et al. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res. 2003;52(6):238–45.
pubmed: 12835895
doi: 10.1007/s00011-003-1162-z
Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists An effective new possibility for treating chronic pruritus. Hautarzt. 2006;57(9):801–7.
pubmed: 16874533
doi: 10.1007/s00105-006-1180-1
Eberlein B, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22(1):73–82.
pubmed: 18181976
Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat. 2005;13(2):97–103.
pubmed: 16324422
Chiurchiu V. Endocannabinoids and immunity. Cannabis Cannabinoid Res. 2016;1(1):59–66.
pubmed: 28861481
pmcid: 5576605
doi: 10.1089/can.2016.0002
Chiurchiu V, Battistini L, Maccarrone M. Endocannabinoid signalling in innate and adaptive immunity. Immunology. 2015;144(3):352–64.
pubmed: 25585882
pmcid: 4557672
doi: 10.1111/imm.12441
Olah A, Szekanecz Z, Biro T. Targeting cannabinoid signaling in the immune system: “High”-ly exciting questions, possibilities, and challenges. Front Immunol. 2017;8:1487.
pubmed: 29176975
pmcid: 5686045
doi: 10.3389/fimmu.2017.01487
Namazi MR. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition. J Eur Acad Dermatol Venereol. 2005;19(3):319–22.
pubmed: 15857457
doi: 10.1111/j.1468-3083.2004.01184.x
pmcid: 15857457
Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000;108(1–2):169–90.
pubmed: 11106790
doi: 10.1016/S0009-3084(00)00195-X
Norooznezhad AH, Norooznezhad F. Cannabinoids: possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Med Hypotheses. 2017;99:15–8.
pubmed: 28110689
doi: 10.1016/j.mehy.2016.12.003
Ihenetu K, et al. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol. 2003;464(2–3):207–15.
pubmed: 12620515
Olah A, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014;124(9):3713–24.
pubmed: 25061872
pmcid: 4151231
doi: 10.1172/JCI64628
Fischer-Stenger K, Dove Pettit DA, Cabral GA, et al. Delta 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post-translational events. J Pharmacol Exp Ther. 1993;267(3):1558–65.
pubmed: 8263818
Olah A, et al. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Exp Dermatol. 2016;25(9):701–7.
pubmed: 27094344
doi: 10.1111/exd.13042
Robinson ES, et al. cannabinoid reduces inflammatory cytokines, tumor necrosis factor-alpha, and type i interferons in dermatomyositis in vitro. J Invest Dermatol. 2017;137(11):2445–7.
pubmed: 28652111
pmcid: 5651184
doi: 10.1016/j.jid.2017.05.035
Wollenberg A, Seba A, Antal AS. Immunological and molecular targets of atopic dermatitis treatment. Br J Dermatol. 2014;170(Suppl 1):7–11.
pubmed: 24720588
doi: 10.1111/bjd.12975
Mimura T, et al. Involvement of the endogenous cannabinoid 2 ligand 2-arachidonyl glycerol in allergic inflammation. Int Arch Allergy Immunol. 2012;159(2):149–56.
pubmed: 22652530
doi: 10.1159/000336167
Rockwell CE, et al. A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells. Biochem Pharmacol. 2008;76(3):353–61.
pubmed: 18571623
doi: 10.1016/j.bcp.2008.05.005
Rockwell CE, et al. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol. 2006;70(1):101–11.
pubmed: 16611855
doi: 10.1124/mol.105.019117
Casares L, et al. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2019;28:101321.
pubmed: 31518892
pmcid: 6742916
doi: 10.1016/j.redox.2019.101321
Stebulis JA, et al. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008;83(19–20):666–70.
pubmed: 18840450
doi: 10.1016/j.lfs.2008.09.004
Klein TW, et al. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health. 1991;32(4):465–77.
pubmed: 1850002
doi: 10.1080/15287399109531496
Glodde N, et al. Differential role of cannabinoids in the pathogenesis of skin cancer. Life Sci. 2015;138:35–40.
pubmed: 25921771
doi: 10.1016/j.lfs.2015.04.003
Oka S, et al. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. Eur J Pharmacol. 2006;538(1–3):154–62.
pubmed: 16647054
doi: 10.1016/j.ejphar.2006.03.021
Fride E, et al. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Neuropharmacology. 2005;48(8):1117–29.
pubmed: 15910887
doi: 10.1016/j.neuropharm.2005.01.023
Lodzki M, et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release. 2003;93(3):377–87.
pubmed: 14644587
doi: 10.1016/j.jconrel.2003.09.001
Sido JM, Nagarkatti PS, Nagarkatti M. Delta(9)-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells. J Leukoc Biol. 2015;98(3):435–47.
pubmed: 26034207
pmcid: 4541500
doi: 10.1189/jlb.3A0115-030RR
Tubaro A, et al. Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins. Fitoterapia. 2010;81(7):816–9.
pubmed: 20450962
doi: 10.1016/j.fitote.2010.04.009
Milando R, Friedman A. Cannabinoids: potential role in inflammatory and neoplastic skin diseases. Am J Clin Dermatol. 2019;20(2):167–80.
pubmed: 30542832
doi: 10.1007/s40257-018-0410-5
Pucci M, et al. Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol. 2013;170(3):581–91.
pubmed: 23869687
pmcid: 3791996
doi: 10.1111/bph.12309
Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2007;45(2):87–92.
pubmed: 17157480
doi: 10.1016/j.jdermsci.2006.10.009
Toth BI, et al. Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. J Invest Dermatol. 2011;131(5):1095–104.
pubmed: 21248768
doi: 10.1038/jid.2010.421
Telek A, et al. Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J. 2007;21(13):3534–41.
pubmed: 17567570
doi: 10.1096/fj.06-7689com
Dobrosi N, et al. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J. 2008;22(10):3685–95.
pubmed: 18596221
doi: 10.1096/fj.07-104877
Galve-Roperh I, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6(3):313–9.
pubmed: 10700234
doi: 10.1038/73171
Grimaldi C, et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res. 2006;312(4):363–73.
pubmed: 16343481
doi: 10.1016/j.yexcr.2005.10.024
Blazquez C, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006;20(14):2633–5.
pubmed: 17065222
doi: 10.1096/fj.06-6638fje
Casanova ML, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111(1):43–50.
pubmed: 12511587
pmcid: 151833
doi: 10.1172/JCI200316116
Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Lett. 2009;285(1):6–12.
pubmed: 19442435
doi: 10.1016/j.canlet.2009.04.005
Sarfaraz S, et al. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 2008;68(2):339–42.
pubmed: 18199524
doi: 10.1158/0008-5472.CAN-07-2785
Armstrong JL, et al. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol. 2015;135(6):1629–37.
pubmed: 25674907
doi: 10.1038/jid.2015.45
Zheng D, et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res. 2008;68(10):3992–8.
pubmed: 18483286
pmcid: 2390870
doi: 10.1158/0008-5472.CAN-07-6594
Carpi S, et al. Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells. Toxicol In Vitro. 2017;40:272–9.
pubmed: 28131817
doi: 10.1016/j.tiv.2017.01.018
Gaspari A, Tyring SK. Tyring, clinical and basic immunodermatology, vol. xviii. Dordrecht: Springer; 2009. p. 812.
Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.
pubmed: 18161745
pmcid: 2693329
doi: 10.1002/path.2277
Garcia-Gonzalez E, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford). 2009;48(9):1050–6.
doi: 10.1093/rheumatology/kep189
Lazzerini PE, et al. Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. J Mol Med (Berl). 2012;90(3):331–42.
doi: 10.1007/s00109-011-0824-5
del Rio C, et al. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-gamma and CB2 pathways. Sci Rep. 2016;6:21703.
pubmed: 26887982
pmcid: 4757881
doi: 10.1038/srep21703
Akhmetshina A, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 2009;60(4):1129–36.
pubmed: 19333940
doi: 10.1002/art.24395
Servettaz A, et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol. 2010;177(1):187–96.
pubmed: 20508030
pmcid: 2893662
doi: 10.2353/ajpath.2010.090763
Gonzalez EG, et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis. 2012;71(9):1545–51.
pubmed: 22492781
doi: 10.1136/annrheumdis-2011-200314
Goswami R, et al. TRPV4 ION channel is associated with scleroderma. J Invest Dermatol. 2017;137(4):962–5.
pubmed: 27889423
doi: 10.1016/j.jid.2016.10.045
Marquart S, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 2010;62(11):3467–76.
pubmed: 20617520
doi: 10.1002/art.27642
Sheriff T, et al. The potential role of cannabinoids in dermatology. J Dermatolog Treat. 2019; p. 1–7.
Mounessa JS, et al. The role of cannabinoids in dermatology. J Am Acad Dermatol. 2017;77(1):188–90.
pubmed: 28416341
doi: 10.1016/j.jaad.2017.02.056
Marks DH, Friedman A. The therapeutic potential of cannabinoids in dermatology. Skin Ther Lett. 2018;23(6):1–5.
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis. ClinicalTrials.gov Identifier: NCT00697710. https://clinicaltrials.gov/ct2/show/NCT00697710 . Accessed 31 Jan 2020.
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis. ClinicalTrials.gov Identifier: NCT03813160. https://clinicaltrials.gov/ct2/show/NCT03813160 . Accessed 31 Jan 2020.
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis. ClinicalTrials.gov Identifier: NCT03398837. https://clinicaltrials.gov/ct2/show/NCT03398837 . Accessed 31 Jan 2020.
Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa. ClinicalTrials.gov Identifier: NCT03929835. https://clinicaltrials.gov/ct2/show/NCT03929835 . Accessed 31 Jan 2020.
Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects. ClinicalTrials.gov Identifier: NCT03997851. https://clinicaltrials.gov/ct2/show/NCT03997851 . Accessed 31 Jan 2020.